Le Lézard
Classified in: Health
Subject: FDA

Perrigo Announces Tentative FDA Approval for a First-to-File Generic Version of Picato® Gel 0.05%



DUBLIN, Nov. 2, 2017 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced it has received tentative approval from the U.S. Food and Drug Administration ("FDA") for the generic version of Picato® Gel (ingenol mebutate) 0.05%. The submission date of Perrigo's Abbreviated New Drug Application matches the first-to-file date posted on FDA's Paragraph IV Patent Certifications list.

Perrigo Company. (PRNewsFoto/Perrigo Company)

Picato® Gel (ingenol mebutate) 0.05% is indicated for the topical treatment of actinic keratosis. Branded market sales for the twelve months ending September 2017 were approximately $16 million.

Perrigo Executive Vice President and President Rx Pharmaceuticals John Wesolowski stated, "This tentative approval, along with the tentative approval previously received for ingenol mebutate gel 0.015%, illustrate the continued dedication of our R&D and regulatory teams as they work to advance our new product pipeline."

About Perrigo 

Perrigo Company plc, a leading global healthcare company, delivers value to its customers and consumers by providing Quality Affordable Healthcare Products®. Founded in 1887 as a packager of home remedies, Perrigo has built a unique business model that is best described as the convergence of a fast-moving consumer goods company, a high-quality pharmaceutical manufacturing organization and a world-class supply chain network. Perrigo is the world's largest manufacturer of over-the-counter ("OTC") healthcare products and supplier of infant formulas for the store brand market. The Company also is a leading provider of branded OTC products throughout Europe and the U.S., as well as a leading producer of "extended topical" prescription drugs. Perrigo, headquartered in Ireland, sells its products primarily in North America and Europe, as well as in other markets, including Australia, Israel and China. Visit Perrigo online at (http://www.perrigo.com).

Forward-Looking Statements

Certain statements in this press release are "forward-looking statements." These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or the negative of those terms or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control, including: the timing, amount and cost of any share repurchases; future impairment charges; the success of management transition; customer acceptance of new products; competition from other industry participants, some of whom have greater marketing resources or larger market shares in certain product categories than the Company does; pricing pressures from customers and consumers; potential third-party claims and litigation, including litigation relating to the Company's restatement of previously-filed financial information; potential impacts of ongoing or future government investigations and regulatory initiatives; general economic conditions; fluctuations in currency exchange rates and interest rates; the consummation of announced acquisitions or dispositions, and the Company's ability to realize the desired benefits thereof; the Company's ability to achieve its guidance; and the Company's ability to execute and achieve the desired benefits of announced cost-reduction efforts and other initiatives.  In addition, the Company may identify and be unable to remediate one or more material weaknesses in its internal control over financial reporting. Furthermore, the Company and/or its subsidiaries may incur additional tax liabilities in respect of 2016 and prior years as a result of any restatement or may be found to have breached certain provisions of Irish company legislation in respect of prior financial statements and if so may incur additional expenses and penalties. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended December 31, 2016, as well as the Company's subsequent filings with the United States Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

 

SOURCE Perrigo Company plc


These press releases may also interest you

at 22:55
K-Bro Linen Inc. (the "Corporation") announced today a dividend of 10.00 cents CDN per common share of the Corporation for the period from October 1 to 31, 2018, to be paid on November 15, 2018 to holders of record of common shares on October 31,...

at 21:36
The World Health Organization (WHO) has appointed philanthropist, humanitarian and health advocate Ray Chambers as its Ambassador for Global Strategy. This new role is designed to support WHO's work to mobilize the...

at 21:03
ICC Labs Inc. (ICC or the Company) confirms that the management information circular dated October 3, 2018 (the Circular), form of proxy and other materials with respect to the Company's proposed plan of arrangement (the Arrangement) with Aurora...

at 21:00
Forecasts by Material (Plastic, Metal, Paper & paperboard, Glass and others), by Sterilization (Chemical, radiation, High Temperature/ Pressure), by Application (Pharmaceutical & Biological, Surgical & Medical Instruments, In Vitro Diagnostic...

at 20:00
LOS ANGELES, Oct. 15, 2018 /PRNewswire-PRWeb/ -- For the first time in U.S. history, a patient's motion has been nearly fully restored, thanks to a new spinal procedure that removes a spine patient's prior fusion in their neck, replacing it with an...

at 20:00
Connected Personal Health Products, Connected Wellness Products, Software & Services, Hospitals, Individual CustomersRead the full report: https://www.reportlinker.com/p05589945 The global connected digital health market is calculated to be worth...




News published on 2 november 2017 at 08:33 and distributed by: